Insider Buying: ReWalk Robotics Ltd. (NASDAQ: RWLK) Major shareholder buys 236,616 shares
ReWalk Robotics Ltd. (NASDAQ: RWLK – Get a rating) major shareholder Global Fund Lp Lind II acquired 236,616 shares of the company in a transaction dated Thursday, June 2. The shares were purchased at an average price of $1.00 per share, for a total transaction of $236,616.00. Following the acquisition, the insider now owns 4,092,022 shares of the company, valued at approximately $4,092,022. The transaction was disclosed in a document filed with the SEC, accessible via the SEC website. Major shareholders who own at least 10% of a company’s stock are required to disclose their sales and purchases to the SEC.
Global Fund Lp Lind II has also recently completed the following transaction(s):
- On Friday May 13, Global Fund Lp Lind II acquired 5,950 shares of ReWalk Robotics. The shares were purchased at an average price of $0.94 per share, for a total transaction of $5,593.00.
- On Wednesday, April 13, Global Fund Lp Lind II acquired 35,551 shares of ReWalk Robotics. The shares were purchased at an average price of $1.11 per share, for a total transaction of $39,461.61.
- On Monday, March 14, Global Fund Lp Lind II acquired 154,810 shares of ReWalk Robotics. The shares were purchased at an average price of $1.01 per share, for a total transaction of $156,358.10.
NASDAQ RWLK traded down $0.02 on Monday, reaching $1.00. The company’s shares had a trading volume of 638,357 shares, compared to its average volume of 452,559. The company has a 50-day moving average price of $1.05 and a 200-day moving average price of $1.14. ReWalk Robotics Ltd. has a 52-week low of $0.85 and a 52-week high of $2.78.
ReWalk Robotics (NASDAQ: RWLK – Get a rating) last released its results on Friday, May 13. The medical device company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimate of ($0.05) by ($0.02). ReWalk Robotics had a negative net margin of 253.78% and a negative return on equity of 16.81%. In the same quarter a year earlier, the company posted ($0.08) earnings per share. Research analysts predict that ReWalk Robotics Ltd. will show -0.2 earnings per share for the current year.
Several research analysts have recently published reports on RWLK shares. HC Wainwright reiterated a “buy” rating on ReWalk Robotics stock in a Wednesday, May 18 report. Zacks Investment Research upgraded ReWalk Robotics shares from a “sell” to a “hold” rating in a Thursday, April 28 research note. To finish, StockNews.com began covering ReWalk Robotics shares in a research note on Thursday, March 31. They issued a “sell” rating on the stock.
Institutional investors have recently changed their stake in the company. CVI Holdings LLC purchased a new stake in ReWalk Robotics during the third quarter worth approximately $896,000. Millennium Management LLC purchased a new stake in ReWalk Robotics during the fourth quarter for a value of approximately $280,000. Goldman Sachs Group Inc. increased its stake in ReWalk Robotics by 150.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 100,224 shares of the medical device company worth $123,000 after buying an additional 60,257 shares in the last quarter. Jane Street Group LLC purchased a new stake in ReWalk Robotics during the third quarter for a value of approximately $89,000. Finally, Virtu Financial LLC purchased a new stake in ReWalk Robotics during the fourth quarter worth approximately $64,000. 9.81% of the shares are currently held by hedge funds and other institutional investors.
About ReWalk Robotics (Get a rating)
ReWalk Robotics Ltd., a medical device company, designs, develops and markets robotic exoskeletons for people with reduced mobility or other medical conditions in the United States, Europe, Asia-Pacific and Africa. The Company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injury and daily use by paraplegics at home and in communities; ReStore, a flexible exosuit for use in the rehabilitation of individuals with lower extremity disability due to stroke in the clinical rehabilitation environment; and the MyoCycle and MediTouch tutor movement biofeedback devices for home or clinic use.
Get news and reviews for ReWalk Robotics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for ReWalk Robotics and related companies with MarketBeat.com’s FREE daily newsletter.